Sarepta Therapeutics Implements Major Restructuring Amid Safety and Pipeline Challenges
TL;DR
Sarepta Therapeutics has laid off over one-third of its workforce, about 500 employees, as part of a major cost-cutting strategy following setbacks in its gene therapy for Duchenne muscular dystrophy. The company is also pausing work on several other gene therapies to save approximately $400 million annually, while promoting top executives with salary increases. These measures aim to improve cash flow and maintain financial stability.
Topics:business#business#cost-cutting#duchenne-muscular-dystrophy#gene-therapy#layoffs#sarepta-therapeutics
- Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move STAT
- Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning Fierce Biotech
- Sarepta Slashes Workforce After Patient Deaths on Gene Therapy (SRPT) Bloomberg.com
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label Yahoo Finance
- Sarepta Therapeutics to Restructure, Lay Off 500 Workers The Wall Street Journal
Want the full story? Read the original reporting
Read on STAT